{"id":697,"date":"2026-02-28T15:34:44","date_gmt":"2026-02-28T15:34:44","guid":{"rendered":"https:\/\/heartcareforyou.in\/blog\/restenosis-definition-clinical-context-and-cardiology-overview\/"},"modified":"2026-02-28T15:34:44","modified_gmt":"2026-02-28T15:34:44","slug":"restenosis-definition-clinical-context-and-cardiology-overview","status":"publish","type":"post","link":"https:\/\/heartcareforyou.in\/blog\/restenosis-definition-clinical-context-and-cardiology-overview\/","title":{"rendered":"Restenosis: Definition, Clinical Context, and Cardiology Overview"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">Restenosis Introduction (What it is)<\/h2>\n\n\n\n<p>Restenosis means \u201cnarrowing again\u201d after a blood vessel has been opened.<br\/>\nIt is a clinical condition and a procedure-related complication.<br\/>\nIt is most commonly discussed after percutaneous coronary intervention (PCI), such as balloon angioplasty or stent placement in coronary arteries.<br\/>\nIt is encountered when symptoms recur or follow-up testing suggests reduced blood flow through a previously treated vessel.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Why Restenosis matters in cardiology (Clinical relevance)<\/h2>\n\n\n\n<p>Restenosis matters because it can partially or fully reverse the goal of revascularization\u2014restoring adequate blood flow to the heart muscle (myocardium). In cardiology training, it is a key concept linking vascular injury, healing biology, and the long-term performance of coronary interventions.<\/p>\n\n\n\n<p>Clinically, restenosis may present with recurrent angina (chest discomfort due to myocardial ischemia) or reduced exercise tolerance, and it can prompt repeat diagnostic testing or repeat revascularization. Although many cases are not immediately life-threatening, restenosis can affect quality of life, functional capacity, and health care utilization.<\/p>\n\n\n\n<p>From a planning standpoint, the possibility of restenosis shapes how clinicians choose devices (for example, drug-eluting stents), consider lesion complexity, and decide whether additional tools (such as intravascular imaging) are needed to optimize results. It also influences follow-up strategy, since recurrent symptoms after PCI require a structured approach to distinguish restenosis from other causes of chest pain (including progression of disease in untreated segments or non-cardiac etiologies).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Classification \/ types \/ variants<\/h2>\n\n\n\n<p>Restenosis is not a single entity; it is typically categorized by <strong>where<\/strong> it occurs and <strong>how<\/strong> it develops.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>By treatment context<\/strong><\/li>\n<li><strong>Post-balloon angioplasty restenosis<\/strong>: restenosis after balloon dilation without a stent. Historically associated with \u201celastic recoil\u201d and vessel remodeling.<\/li>\n<li>\n<p><strong>In-stent restenosis (ISR)<\/strong>: restenosis occurring within a stented segment. This is a common modern use of the term Restenosis.<\/p>\n<\/li>\n<li>\n<p><strong>By device\/drug context<\/strong><\/p>\n<\/li>\n<li><strong>Bare-metal stent (BMS) restenosis<\/strong>: more closely tied to neointimal hyperplasia (tissue growth inside the stent).<\/li>\n<li>\n<p><strong>Drug-eluting stent (DES) restenosis<\/strong>: often reduced compared with BMS in many settings, but still possible and influenced by mechanical factors (stent underexpansion) and biology (healing response, neoatherosclerosis).<\/p>\n<\/li>\n<li>\n<p><strong>By pattern\/location relative to the stent<\/strong><\/p>\n<\/li>\n<li><strong>Focal<\/strong>: a short segment of renarrowing, sometimes related to a localized mechanical issue.<\/li>\n<li><strong>Diffuse<\/strong>: longer segments of narrowing, which may reflect a broader proliferative response or multiple mechanical contributors.<\/li>\n<li><strong>Edge restenosis<\/strong>: at the proximal or distal margin of a stent, sometimes where treated and untreated vessel meet.<\/li>\n<li>\n<p><strong>In-segment vs in-stent<\/strong>: \u201cin-stent\u201d refers to the stent itself; \u201cin-segment\u201d may include the stent and its edges, depending on definition used.<\/p>\n<\/li>\n<li>\n<p><strong>By timing (conceptual, not absolute)<\/strong><\/p>\n<\/li>\n<li><strong>Early restenosis<\/strong>: often related to procedural\/mechanical factors (residual narrowing, recoil, underexpansion) and early healing responses.<\/li>\n<li><strong>Late restenosis<\/strong>: may involve longer-term processes such as neoatherosclerosis (atherosclerotic change developing within the treated segment over time).<\/li>\n<\/ul>\n\n\n\n<p>These categories are used to frame mechanism and management, but real-world classification can vary by clinician and case.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Relevant anatomy &amp; physiology<\/h2>\n\n\n\n<p>Restenosis is fundamentally about <strong>coronary artery structure and the vessel\u2019s response to injury<\/strong>.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Coronary circulation basics<\/strong><\/li>\n<li>The coronary arteries supply oxygenated blood to the myocardium.<\/li>\n<li>Flow is influenced by epicardial vessel caliber (large surface arteries) and microvascular resistance (small vessels within the heart muscle).<\/li>\n<li>\n<p>A focal epicardial narrowing can limit the ability to increase flow during stress, producing demand\u2013supply mismatch and ischemia.<\/p>\n<\/li>\n<li>\n<p><strong>Arterial wall layers<\/strong><\/p>\n<\/li>\n<li><strong>Intima<\/strong>: the innermost layer, lined by endothelial cells that regulate thrombosis, inflammation, and vasomotor tone.<\/li>\n<li><strong>Media<\/strong>: smooth muscle cell layer that contributes to vessel tone and structural integrity.<\/li>\n<li>\n<p><strong>Adventitia<\/strong>: outer layer containing connective tissue and small vessels (vasa vasorum).<\/p>\n<\/li>\n<li>\n<p><strong>What PCI changes<\/strong><\/p>\n<\/li>\n<li>Balloon angioplasty and stent implantation deliberately disrupt plaque and stretch the vessel to enlarge the lumen.<\/li>\n<li>This mechanical intervention can injure the endothelium and deeper arterial layers.<\/li>\n<li>The vessel responds with healing processes\u2014some beneficial (re-endothelialization), some potentially lumen-limiting (neointimal tissue growth or remodeling).<\/li>\n<\/ul>\n\n\n\n<p>Understanding restenosis requires connecting the procedure (mechanical dilation and scaffolding) to the biology of repair, inflammation, and long-term vascular remodeling.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Pathophysiology or mechanism<\/h2>\n\n\n\n<p>The central mechanism of Restenosis is <strong>lumen loss after an initially successful opening<\/strong>, driven by overlapping mechanical and biological processes. The dominant contributors depend on whether a stent is present and on patient and lesion characteristics.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Endothelial injury and healing<\/strong><\/li>\n<li>PCI disrupts the endothelial layer and exposes subendothelial structures.<\/li>\n<li>This triggers platelet activation and inflammatory signaling.<\/li>\n<li>\n<p>Healing involves endothelial recovery, but the balance of healing vs excessive tissue response varies by patient and device.<\/p>\n<\/li>\n<li>\n<p><strong>Neointimal hyperplasia (tissue growth within the lumen)<\/strong><\/p>\n<\/li>\n<li>Smooth muscle cells can migrate from the media, proliferate, and produce extracellular matrix.<\/li>\n<li>The resulting neointimal tissue can narrow the lumen, particularly within stents where the metal scaffold prevents outward expansion as compensation.<\/li>\n<li>\n<p>Drug-eluting stents release antiproliferative agents designed to reduce this response, but it may still occur.<\/p>\n<\/li>\n<li>\n<p><strong>Negative (constrictive) remodeling and recoil<\/strong><\/p>\n<\/li>\n<li>After balloon angioplasty without a stent, the vessel can partially recoil (elastic recoil).<\/li>\n<li>Over time, constrictive remodeling may also reduce lumen size.<\/li>\n<li>\n<p>Stents reduce recoil by acting as a scaffold, shifting the main mechanism toward in-stent tissue growth and mechanical factors.<\/p>\n<\/li>\n<li>\n<p><strong>Mechanical\/procedural contributors<\/strong><\/p>\n<\/li>\n<li><strong>Stent underexpansion<\/strong>: the stent does not fully expand to match vessel size, leaving a smaller lumen and altered flow patterns.<\/li>\n<li><strong>Stent malapposition or fracture<\/strong>: can contribute to abnormal healing or focal restenosis in some cases.<\/li>\n<li>\n<p><strong>Geographic miss<\/strong>: incomplete coverage of diseased segments or transition zones may contribute to edge problems.<\/p>\n<\/li>\n<li>\n<p><strong>Neoatherosclerosis<\/strong><\/p>\n<\/li>\n<li>Over time, atherosclerotic changes may develop within previously treated segments.<\/li>\n<li>This process can contribute to late lumen loss and may resemble native coronary artery disease behavior, including plaque formation within the treated area.<\/li>\n<\/ul>\n\n\n\n<p>No single mechanism explains all cases; restenosis is best understood as a spectrum shaped by vascular biology, device choice, lesion features, and procedural technique.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Clinical presentation or indications<\/h2>\n\n\n\n<p>Restenosis is usually suspected in patients with prior coronary intervention who develop symptoms or objective signs of ischemia. Common scenarios include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Recurrence of <strong>exertional chest discomfort<\/strong> after prior improvement post-PCI  <\/li>\n<li><strong>New or worsening angina<\/strong> pattern (stable or unstable features depending on context)  <\/li>\n<li>Reduced exercise tolerance, early fatigue, or exertional breathlessness that raises concern for ischemia  <\/li>\n<li>Abnormal findings on <strong>stress testing<\/strong> performed for symptoms or risk assessment  <\/li>\n<li>Evidence of ischemia on imaging (for example, perfusion deficits) in a territory supplied by a previously treated artery  <\/li>\n<li>Incidental detection of significant renarrowing on coronary imaging performed for another reason (varies by protocol and patient factors)<\/li>\n<\/ul>\n\n\n\n<p>Symptoms are not specific to restenosis. Clinicians also consider alternative explanations such as progression of atherosclerosis in other segments, coronary vasospasm, microvascular dysfunction, anemia, lung disease, or non-cardiac chest pain.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Diagnostic evaluation &amp; interpretation<\/h2>\n\n\n\n<p>Evaluation aims to (1) determine whether symptoms represent myocardial ischemia, and (2) identify whether the treated segment is responsible.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>History and clinical context<\/strong><\/li>\n<li>Timing relative to PCI, symptom pattern, exertional triggers, and response to rest or nitroglycerin (if used in a given setting).<\/li>\n<li>\n<p>Review of the original PCI details can be informative (target vessel, stent type, lesion complexity), though availability varies.<\/p>\n<\/li>\n<li>\n<p><strong>Physical exam<\/strong><\/p>\n<\/li>\n<li>Often nonspecific for restenosis itself.<\/li>\n<li>\n<p>Used to assess alternative or contributing conditions (heart failure signs, valvular disease clues, blood pressure issues).<\/p>\n<\/li>\n<li>\n<p><strong>Electrocardiogram (ECG)<\/strong><\/p>\n<\/li>\n<li>May be normal at rest.<\/li>\n<li>\n<p>Ischemic changes during symptoms can support an ischemic mechanism but do not localize reliably to restenosis without other data.<\/p>\n<\/li>\n<li>\n<p><strong>Laboratory testing<\/strong><\/p>\n<\/li>\n<li>Cardiac biomarkers are considered when acute coronary syndrome is suspected; restenosis can present with unstable symptoms in some cases, but many cases present as stable angina.<\/li>\n<li>\n<p>Labs also help evaluate comorbid contributors (for example, anemia), depending on presentation.<\/p>\n<\/li>\n<li>\n<p><strong>Noninvasive ischemia testing<\/strong><\/p>\n<\/li>\n<li><strong>Exercise ECG testing<\/strong> may be used when appropriate, with interpretation based on ischemic patterns and symptom reproduction.<\/li>\n<li><strong>Stress imaging<\/strong> (stress echocardiography, nuclear perfusion imaging, or stress cardiac magnetic resonance) can assess ischemia location and severity in a functional sense.<\/li>\n<li>\n<p>These tests support the probability of a flow-limiting problem but do not directly visualize the stented segment.<\/p>\n<\/li>\n<li>\n<p><strong>Coronary imaging<\/strong><\/p>\n<\/li>\n<li><strong>Coronary angiography<\/strong> is the traditional reference for visualizing lumen narrowing in epicardial arteries and stents.<\/li>\n<li>\n<p><strong>Coronary computed tomography angiography (CCTA)<\/strong> may evaluate coronary anatomy noninvasively in selected patients, but image quality in stented segments can be limited depending on stent size, motion, and scanner capabilities (varies by protocol and patient factors).<\/p>\n<\/li>\n<li>\n<p><strong>Physiologic lesion assessment (invasive)<\/strong><\/p>\n<\/li>\n<li><strong>Fractional flow reserve (FFR)<\/strong> or <strong>instantaneous wave-free ratio (iFR)<\/strong> may be used during angiography to determine whether a narrowing is functionally significant (flow-limiting).<\/li>\n<li>\n<p>This helps separate visually moderate narrowing from lesions that actually reduce blood flow.<\/p>\n<\/li>\n<li>\n<p><strong>Intravascular imaging (invasive)<\/strong><\/p>\n<\/li>\n<li><strong>Intravascular ultrasound (IVUS)<\/strong> and <strong>optical coherence tomography (OCT)<\/strong> can identify mechanisms such as stent underexpansion, tissue growth pattern, edge disease, or stent fracture.<\/li>\n<li>Imaging findings can guide procedural strategy when repeat intervention is considered.<\/li>\n<\/ul>\n\n\n\n<p>Interpretation generally integrates symptoms, ischemia evidence, and anatomic\/physiologic assessment, rather than relying on a single test.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Management overview (General approach)<\/h2>\n\n\n\n<p>Management depends on symptoms, evidence of ischemia, the mechanism of restenosis, and overall coronary disease burden. The approach commonly blends medical therapy and, when appropriate, repeat revascularization.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Medical therapy and risk factor management<\/strong><\/li>\n<li>Antianginal medications may be used to reduce symptoms and improve exercise tolerance.<\/li>\n<li>Preventive therapy for atherosclerotic cardiovascular disease (for example, lipid lowering, blood pressure control, diabetes management, and smoking cessation support) is relevant because restenosis occurs in the broader context of coronary artery disease.<\/li>\n<li>\n<p>Antiplatelet therapy is an important part of post-PCI care; the specific regimen and duration vary by clinician and case, and by bleeding vs ischemic risk.<\/p>\n<\/li>\n<li>\n<p><strong>Repeat percutaneous coronary intervention (PCI)<\/strong><\/p>\n<\/li>\n<li>Options may include:<ul>\n<li><strong>Repeat stenting<\/strong>, often with contemporary drug-eluting stent technology in suitable anatomy.<\/li>\n<li><strong>Drug-coated balloon (DCB) angioplasty<\/strong> in selected settings, where an antiproliferative drug is delivered without adding another metal layer.<\/li>\n<li><strong>Lesion preparation<\/strong> techniques (for example, specialized balloons, cutting\/scoring balloons) when resistant tissue or underexpansion is suspected.<\/li>\n<li><strong>Atherectomy<\/strong> (plaque modification) in selected cases, particularly when calcification or underexpanded stents are involved; selection varies by operator experience and patient factors.<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>Intravascular imaging is often used to clarify mechanism and optimize results, though its use varies by protocol and case complexity.<\/p>\n<\/li>\n<li>\n<p><strong>Coronary artery bypass grafting (CABG)<\/strong><\/p>\n<\/li>\n<li>Surgery may be considered when restenosis is recurrent, anatomy is complex (such as diffuse disease or multiple lesions), or when there is multivessel coronary disease where surgical revascularization offers a more durable strategy for a given patient profile.<\/li>\n<li>\n<p>The choice between PCI and CABG is individualized and incorporates coronary anatomy, comorbidities, and patient goals.<\/p>\n<\/li>\n<li>\n<p><strong>When conservative management may be reasonable<\/strong><\/p>\n<\/li>\n<li>If symptoms are minimal and objective ischemia is not demonstrated, clinicians may prioritize medical therapy and monitoring rather than repeat intervention.<\/li>\n<li>Decisions depend on overall risk and patient-specific factors, not on restenosis alone.<\/li>\n<\/ul>\n\n\n\n<p>This is an educational overview; real-world management is individualized and shaped by local protocols and multidisciplinary decision-making.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Complications, risks, or limitations<\/h2>\n\n\n\n<p>Restenosis and its evaluation\/treatment have several potential risks and limitations, many of which are context-dependent.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical risks of restenosis<\/strong><\/li>\n<li>Recurrent angina and reduced functional capacity<\/li>\n<li>Need for repeat testing and repeat procedures<\/li>\n<li>\n<p>In some cases, presentation as unstable symptoms requiring urgent evaluation<\/p>\n<\/li>\n<li>\n<p><strong>Risks related to repeat angiography or PCI<\/strong><\/p>\n<\/li>\n<li>Bleeding or vascular access complications<\/li>\n<li>Contrast-associated kidney injury risk in susceptible patients<\/li>\n<li>Allergic reactions to contrast (uncommon, variable by patient factors)<\/li>\n<li>Procedural complications such as vessel dissection, perforation, or no-reflow (risk varies by lesion complexity)<\/li>\n<li>\n<p>Radiation exposure during fluoroscopic procedures<\/p>\n<\/li>\n<li>\n<p><strong>Stent-related considerations<\/strong><\/p>\n<\/li>\n<li>Adding additional stent layers can complicate future interventions and may affect vessel mechanics.<\/li>\n<li>\n<p>Stent thrombosis is a distinct entity from restenosis but is part of the broader risk discussion after stenting; the balance of antiplatelet therapy benefit and bleeding risk varies by clinician and case.<\/p>\n<\/li>\n<li>\n<p><strong>Diagnostic limitations<\/strong><\/p>\n<\/li>\n<li>Symptoms are nonspecific; not all post-PCI chest pain is restenosis.<\/li>\n<li>Noninvasive tests may not localize a lesion precisely, and some modalities have reduced accuracy in specific scenarios (for example, imaging inside certain stents).<\/li>\n<li>Angiographic appearance does not always predict functional significance without physiologic assessment.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Prognosis &amp; follow-up considerations<\/h2>\n\n\n\n<p>Prognosis after restenosis depends on whether the narrowing is flow-limiting, how much myocardium is affected, and whether the mechanism is correctable (for example, a focal underexpanded segment vs diffuse proliferative changes). Many patients can achieve symptom improvement with optimized therapy, and repeat interventions can be effective in selected cases, though recurrent restenosis can occur.<\/p>\n\n\n\n<p>Factors that often influence outcomes and follow-up planning include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient factors<\/strong>: diabetes mellitus, ongoing smoking, chronic kidney disease, and the overall burden of atherosclerosis can affect vascular healing and long-term coronary risk.<\/li>\n<li><strong>Lesion and procedure factors<\/strong>: vessel size, lesion length, calcification, bifurcation anatomy, and stent expansion quality can shape recurrence risk and procedural durability.<\/li>\n<li><strong>Device factors<\/strong>: stent type and prior layers of metal can influence future strategy.<\/li>\n<li><strong>Physiology and symptoms<\/strong>: the presence of objective ischemia and symptom severity often guide intensity of evaluation and need for revascularization.<\/li>\n<li><strong>Medication tolerance and adherence<\/strong>: preventive therapies and antiplatelet strategies are central to overall coronary disease management; plans vary by clinician and case.<\/li>\n<\/ul>\n\n\n\n<p>Follow-up is generally oriented around symptom monitoring, functional status, and risk factor control, with additional testing guided by clinical change rather than routine imaging in all patients (varies by protocol and patient factors).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Restenosis Common questions (FAQ)<\/h2>\n\n\n\n<p><strong>Q: What does Restenosis mean in plain language?<\/strong><br\/>\nIt means a treated blood vessel has become narrow again after it was previously opened. In cardiology, this most often refers to a coronary artery segment treated with balloon angioplasty and\/or a stent. The renarrowing can reduce blood flow during exertion and recreate symptoms of ischemia.<\/p>\n\n\n\n<p><strong>Q: Is Restenosis the same as a new blockage?<\/strong><br\/>\nNot exactly. Restenosis occurs at or near a previously treated site and is related to healing responses and mechanical factors after the procedure. A \u201cnew blockage\u201d often refers to progression of atherosclerosis in a different, previously untreated segment, though both can occur in the same patient.<\/p>\n\n\n\n<p><strong>Q: How is in-stent restenosis different from stent thrombosis?<\/strong><br\/>\nIn-stent restenosis is gradual renarrowing, often from tissue growth within the stent or mechanical issues like underexpansion. Stent thrombosis is a clot forming in the stent, which can present suddenly and may cause an acute coronary syndrome. They are different processes, though both are important considerations after PCI.<\/p>\n\n\n\n<p><strong>Q: What symptoms might suggest Restenosis?<\/strong><br\/>\nA common clue is return of exertional chest discomfort after an initial period of improvement following PCI. Some people notice reduced exercise tolerance or exertional breathlessness. Symptoms are not specific, so clinicians typically evaluate for other cardiac and non-cardiac causes as well.<\/p>\n\n\n\n<p><strong>Q: What tests are used to check for Restenosis?<\/strong><br\/>\nClinicians often start with a clinical assessment and may use stress testing to look for evidence of ischemia. Coronary angiography can directly visualize the treated segment, and invasive physiologic testing (FFR\/iFR) can assess whether a narrowing limits blood flow. Intravascular imaging (IVUS or OCT) can help determine the mechanism when planning treatment.<\/p>\n\n\n\n<p><strong>Q: Does Restenosis always need another procedure?<\/strong><br\/>\nNot always. Management depends on symptoms, objective evidence of ischemia, and the characteristics of the narrowing. Some cases may be managed with medical therapy and monitoring, while others may benefit from repeat PCI or, less commonly, bypass surgery.<\/p>\n\n\n\n<p><strong>Q: If Restenosis happens once, can it happen again?<\/strong><br\/>\nRecurrent restenosis can occur, especially when contributing factors persist (such as complex lesion anatomy or underexpansion) or when multiple stent layers are present. Using intravascular imaging to identify the mechanism can help tailor the approach, but recurrence risk varies by patient and case.<\/p>\n\n\n\n<p><strong>Q: How long after a stent can Restenosis occur?<\/strong><br\/>\nIt can occur months after PCI, and in some cases later processes such as neoatherosclerosis can contribute over longer periods. The timing is influenced by device type, healing response, and mechanical factors. Clinicians interpret timing alongside symptoms and test results rather than relying on timing alone.<\/p>\n\n\n\n<p><strong>Q: What is the \u201cnext step\u201d if Restenosis is suspected?<\/strong><br\/>\nThe next step is typically to confirm whether symptoms reflect myocardial ischemia and whether the previously treated segment is responsible. This may involve stress testing, coronary imaging, or invasive evaluation depending on the clinical scenario. The exact pathway varies by clinician and case, balancing urgency, risk, and diagnostic clarity.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Restenosis means \u201cnarrowing again\u201d after a blood vessel has been opened. It is a clinical condition and a procedure-related complication. It is most commonly discussed after percutaneous coronary intervention (PCI), such as balloon angioplasty or stent placement in coronary arteries. It is encountered when symptoms recur or follow-up testing suggests reduced blood flow through a previously treated vessel.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-697","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts\/697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/comments?post=697"}],"version-history":[{"count":0,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts\/697\/revisions"}],"wp:attachment":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/media?parent=697"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/categories?post=697"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/tags?post=697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}